You are here

Home » Content

ERİTROPOİETİNE BAĞLI DEMİR TÜKETİMİNİN SERUM ALİMİNYUM DÜZEYİNE ETKİSİ

THE EFFECT OF IRON UTILIZATION DUE TO ERYTHROPOIETIN (EPO) TREATMENT ON SERUM ALUMINIUM (AL) LEVELS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1994

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Tlıe status of body iron stores may influence serum and tissue AL levels. In order to clarify the effect of EPO related iron utilization on serum AL levels we studied serum AL and ferritin (FER) levels in hemodialysis patients. Tlıe patients were classified into three groups according to their serum FER levels: serum FER < 100 ng/ml(n=3), FER between 100-800 ng/ml(n=29) and FER>800 ng/ml (n=9). Mean serum Al concentrations were not significantly different between the three groups. Tliis result suggests EPO related iron utilization does not affect serum AL levels and more studies are needed.
Bookmark/Search this post with
Abstract (Original Language): 
Vücut depo demirinin dununu serum ve doku alüminyum (AL) düzeyini etkileyebilir.Hemodiyaliz hastalarında eritropoietine (EPO) bağlı demir tüketiminin serum AL düzeyine etkisini araştırmak amacı ile serum AL ve ferritin (FER) düzeyine bakılmıştır.Hasta-lar serum FER düzeylerine göre 3gruba ayrılmıştır; serum FER < 100 ng/ml(n = 13), FER 100-800 ng/ml arası(n =29) ve Fer>800ng/ml(n = 9). Üçgruptada or¬talama serum Al düzeyleri arasında anlamlı bir farklı¬lık saptanmamıştır.Bu sonuç EPOya bağlı demir tüke¬timinin serum AL düzeylerini telkin etmektedir ve bu konuda yeni çalışmalaraihtiyaç vardır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_50.pdf
  • 2
56-58
  • Turkish

REFERENCES

References: 

1- D'Haese PC, Clement JP, ELseviers MM, Lamberts LV, VAN de Vyver FL,Visser WJ, De broe ME. Value of serum aluminium monitoring in dialysis patients: a multicentre study. Nephrol Dial Transplant 1990;5:45-53.
2- Casti S, Campise M, Ponticelli C. Aluminium interference in the treatment with recombinant human erythropoietin. Contrib Nephrol 1990;87-94.
3- Muirhead N, Hodsman AB, Hollomby DJ, Cordy PE. THE role of aluminium and parathyroid hormone in erythropoietin resistance in haemodialysis patients.Nephrol Dial Transplant 1991;6:342-345.
4- Bia MJ, Cooper K.SCHnall S, Duffy T, Hendler E, Maqlluche H, Solomon L. Aluminium induced anemia:pathogenesis and treatment in patients on chronic hemodialysis. Kidney Int 1989;3 6:852-858.
5- Abreo K, Glass J. Cellular, biochemical, and molecular mechanisms of aluminium toxicity. Nephrol dial Transplant 1993;Suppl 1:5-11. v 6-Chazan JA, Lew NL, Lowrie EG. Increased serum aluminium. Arch Intern Med 1991;151:319-322.
7- Consensus conference.Diagnosis and treatment of aluminium overload in end-stage renal failure patients. Nephrol Dial Transplant 1993;Suppl 1:1-4.
8- Cannata AB, Lopez JBD. Insights into the complex aluminium and iron relationship . Nephrol Dial Transplant 1991;6:605-607.
9- Ittel TH. Determinants of gastrointestinal absorption and distribution of aluminium in health and uremia. Nephrol Dial Transplant 1993;Suppl 1:17-24.
10-Eschbach JW.EgrieJC, Dowing MR, Browne JK, Adamson JW. Correction of the anemia of end stage renal disease with recombinant human erythropoietin; results of a combined phase I and II clinical trial.N Engl J Med 1987;310:73-78.
11- Horl WH, dreyling K, Steinhauer HB, Engelhardt R,
Schollmeyer P. Iron status on dialysis patients under rhuEPO
therapy. Contrib Nephrol 1990;87:78-86.
12- Lugowski S, Smith DC, VAN Loon JC. THE determination of Al,Cr,Co,Fe and Ni in whole blood by electrothermal atomic
57
absorption spectrophotometry. J Biomedical Materials Research 1987; 21:657-74.
13- Trapp GA. Plasma aluminium is bound to transferrin. Life Sci 1983;33:311-316.
14- Ittel TH, Schulpin A, Sieberth HG.Relationship between body iron Stores and intestinal absorbtion of aluminium
(absract). Nephrol Dial Transplant 1991;6:817.
15- Ittel TH, Schulpin A.Sieberth HG. Body iron stores donot affect the enchanced intestinal absorption of aluminium in uremia(abstact). J Am Soc Nephrol 1991;2:611.
16- Cannata JB, Suarez C, Cuesta MV, Rodriguez RR, Ailende MT, Herrera J,Perez Llanderal J. Gastrointestinal aluminium absorbtion:is it modulated by the iron-absorptive mechanism
Proc Eur Dial Transplant Assoc 1984:21:354-359.
17- Abreo K, Glass J, Sella ML. Aluminium inhibits hemoglobin synthesis but enhances iron uptake in Friend erytholeukemia cells. Kidney Int 1990;37:677-681.
18- Fernandez Menendez MJ, Fell GS, Brock JH, Cannata JB.
Aluminium uptake by intestinal cells.Effect of iron status and precomplexation. Nephrol Dial Transplant 1991;6:672-674.
19- Cannata JB,Olaizola In, Gomez- Alonso C, Menendez-Fraga p, Alonso- Suarez M,Diaz-Lopez JB. Serum aluminium transport and aluminium uptake in chronic renal failure :role of iron and aluminium metabolism. Nephron 1993;65:141-146.
20- Vanuytsel JL, D'Haese PC, Couttenye MM, DE Broe ME. Highe serum aluminium concentrations in iron-depleted dialysis patients.Nephrol DialTransplant 1992;7:177.
21- Huang YY, Huang CC, Lum PS, Wu MS.Leu ML. Effect of body iron stores on serum aluminium level in hemodialysis
patients. Nephron 1992;61:158-162.
22- Hosokawa S, Yoshida O. Effects of erythropoietin on trace elements in patients with chronic renal failure undergoing
hemodialysis. Nephron 1993;65:414-417.
23- Van de Vyver FL, Vanheulle AA, Majelyne WM et al. Serum ferritin as a guide for iron stores in chronic hemodialysis patients. Kidney international 1984;26:451-458.
58

Thank you for copying data from http://www.arastirmax.com